The CF Foundation Awards Arcturus Therapeutics Up to $15M for RNA Therapy
The Cystic Fibrosis Foundation has increased its award to Arcturus Therapeutics to up to $15 million to develop a mutation-agnostic therapy for people with cystic fibrosis.read more
View ArticleICER Announces Assessment of Triple-Combination Therapy
The Institute for Clinical and Economic Review (ICER) is developing an assessment of the clinical effectiveness and value of the triple combination (also known as elexacaftor/tezacaftor/ivacaftor). The...
View ArticleFoundation Funds Early Stage Clinical Trial of a Potential Nonsense Mutation...
These mutations cause the cells to stop the production of the CFTR protein midway through the process, resulting in shortened, non-functional protein that the cell recognizes as defective and...
View ArticleEnterprise Therapeutics Awarded Up to $7M to Develop Mucus-Clearance Drug for...
The Cystic Fibrosis Foundation has awarded up to $7 million to Enterprise Therapeutics to develop a compound that targets a non-CFTR chloride channel in lung cells. If successful, the drug could help...
View ArticleICER Posts Draft Scoping Document for Assessment of Triple Combination Therapy
The Institute for Clinical and Economic Review (ICER) recently posted a draft scoping document to outline their planned assessment of the clinical effectiveness and value of the triple combination...
View ArticleCF Foundation Celebrates FDA Approval of Triple Combination
The U.S. Food and Drug Administration has approved the use of the triple-combination modulator elexacaftor/tezacaftor/ivacaftor (Trikafta™) for people with cystic fibrosis ages 12 and older who have at...
View ArticleCystic Fibrosis Foundation Is Exploring New CFTR Modulators
The Cystic Fibrosis Foundation announced today that it has licensed a compound to the biopharmaceutical company AbbVie to develop into a potential CFTR modulator treatment.read more
View ArticleMensaje del director ejecutivo a la comunidad: lanzamiento del Path to a Cure...
El futuro para las personas con Fibrosis Quística (FQ) nunca fue tan prometedor. La búsqueda incesante de la CF Foundation de un futuro y un presente mejores para las personas con FQ, combinada con...
View ArticleCystic Fibrosis Foundation Launches $500 Million Path to a Cure
BETHESDA, Md. -- Today the Cystic Fibrosis Foundation unveiled its Path to a Cure, an ambitious research agenda to deliver treatments for the underlying cause of the disease and a cure for every person...
View ArticleFoundation Announces 2020 Volunteer Leadership Conference Co-Chairs
Ray Poole and Julie Riedy to lead efforts in Washington, D.C., for volunteer conference, Until CF Stands for Cure Found.read more
View ArticleCircuit Court Rules on ACA in Texas v. United States
On Dec. 18, the Fifth Circuit Court of the United States issued a decision in Texas v. United States, ruling the individual mandate unconstitutional but sending the case back down to the district court...
View ArticleCF Foundation Awards Leading Research Organization Funding to Screen for...
The Cystic Fibrosis Foundation awarded nearly $700,000 to Calibr, the drug discovery and development arm of Scripps Research, to screen for a compound that could be used to treat Burkholderia cepacia...
View ArticleChoate Construction Named the Top 2019 National Corporate Team
Choate Construction's National Corporate Team raised over $670,000 for the Cystic Fibrosis Foundation in 2019, serving as a role model for corporations looking to integrate philanthropy into their...
View ArticleCystic Fibrosis Foundation Supports Development of Non-Porcine Enzyme Therapy
Between 85 and 90 percent of people with CF are pancreatic insufficient. This occurs when thick, sticky pancreatic secretions block the release of enzymes needed to break down food for digestion. With...
View ArticleICER Issues Draft Evidence Report for Assessment of Trikafta
The Institute for Clinical and Economic Review (ICER) recently posted a draft evidence report to outline their initial assessment of the clinical effectiveness and value of CFTR modulators, including...
View ArticleMore than 200 Advocates Urge Congress for More Antibiotics During March on...
More than 200 advocates gathered on Capitol Hill during the Cystic Fibrosis Foundation's 14th Annual March on the Hill, championing antibiotic research and development and other policy needs on behalf...
View ArticleOver 10,000 Home Spirometers Provided for Virtual Care Visits Through CF...
Since the start of the pandemic, the CF care center network has seen a five-fold increase in virtual care visits, allowing most people with CF to maintain vital connections to their care teams without...
View ArticleCF Foundation Awards Funding for First-Ever Controlled Clinical Study of...
The Cystic Fibrosis Foundation awarded up to $5 million to Armata Pharmaceuticals for the first-ever controlled clinical study of phage therapy in CF, reaffirming the Foundation's commitment to advance...
View ArticleCF Foundation Awards Up to $5.6 Million to Develop Novel Antibiotic to Fight...
As part of the Infection Research Initiative , the Cystic Fibrosis Foundation awarded the pharmaceutical company Microbion $5.6 million to develop a novel antibiotic, pravibismane, that could help...
View ArticleCF Foundation Invests up to $14M in Effort to Solve Key Challenges to Gene...
BETHESDA, Md. -- Today the Cystic Fibrosis Foundation announced an investment of up to $14 million in 4D Molecular Therapeutics (4DMT) to develop a customized vehicle to deliver a healthy cystic...
View ArticleCF Foundation Leadership Represents the CF Community Voice During Global...
On July 9, the Cystic Fibrosis Foundation's president and CEO, Dr. Michael P. Boyle, participated in the launch of the AMR Action Fund , a collective venture that expects to invest over $1 billion into...
View ArticleCF Foundation Announces 2020 Impact Grant Recipients
The Cystic Fibrosis Foundation announced the recipients of its fifth annual Impact Grants, which provide up to $10,000 per year of funding to individuals and organizations who are leading unique...
View ArticleCystic Fibrosis Foundation and Longwood Fund Launch CF Incubator
BETHESDA, Md. -- Today the Cystic Fibrosis Foundation announced a collaboration with Longwood Fund, a biotech-focused venture capital firm, to accelerate innovative therapies for cystic fibrosis....
View ArticleCF Foundation Awards Nearly $15 Million to Spur Infection Research
Today, the Cystic Fibrosis Foundation announced 33 academic research awards focused on improving outcomes from difficult-to-treat infections that impact people with CF. The awards, totaling nearly $15...
View ArticleCF Foundation Leaders Provide Expertise During ICER Public Meeting
On Aug. 27, the Institute for Clinical and Economic Review (ICER) hosted a virtual public meeting as part of their assessment of the clinical and cost effectiveness of CFTR modulator therapies ,...
View ArticleCystic Fibrosis Foundation Announces Nine Research Agreements to Advance Its...
BETHESDA, Md. -- Today, the Cystic Fibrosis Foundation announced $1.7 million in new research funding to drive progress on its Path to a Cure . The awards, to seven academic institutions and two...
View ArticleCF Foundation Awards Up to $2M to Eloxx for Additional Support for Studies...
BETHESDA, Md. -- Today, the Cystic Fibrosis Foundation announced a new award of up to $2 million to Eloxx Pharmaceuticals Inc.read more
View ArticleCF Foundation Has Awarded Up to $3M to Kinnear Pharmaceuticals for...
BETHESDA, Md. -- The Cystic Fibrosis Foundation has awarded up to $3 million to Kinnear Pharmaceuticals to conduct preclinical testing of a broad-spectrum anti-infective that has the potential to treat...
View ArticleCF Foundation Awards Up to $2.17 Million to Beyond Air to Develop Portable...
BETHESDA, Md. -- Today, the Cystic Fibrosis Foundation announced that it has awarded up to $2.17 million to Beyond Air ® to support the development of a portable inhaled nitric oxide treatment for...
View ArticleCF Foundation Awards Contract to Life Edit Therapeutics to Explore Gene...
BETHESDA, Md. -- Today, the Cystic Fibrosis Foundation announced that it has awarded up to $400,000 to Life Edit Therapeutics Inc.read more
View ArticleWilliam Skach, Chief Scientific Officer, to Retire From the CF Foundation
In 2014, Dr. Skach joined the CF Foundation to oversee the Foundation's investments in basic research and venture philanthropy programs at a pivotal time for CF science. Under his leadership, the...
View ArticleCF Foundation Responds to NIH Call for Information on Diversity and Inclusion
Cystic fibrosis affects people of different racial and ethnic backgrounds. As of 2019, nearly five percent of people with CF in the U.S. identify as Black and nearly 10 percent identify as Hispanic....
View ArticleCF Foundation Invests Up to $8.4M in SpliSense for the Development of...
BETHESDA, Md. -- Today, the Cystic Fibrosis Foundation announced that it will invest up to $8.4 million in SpliSense's Series B funding round to develop an antisense oligonucleotide (ASO) therapy for...
View ArticleCF Foundation Funds Three New Research Awards to Advance its Path to a Cure...
BETHESDA, Md. -- Today, the Cystic Fibrosis Foundation announced three new research awards as part of its Path to a Cure initiative to accelerate the development of treatments for the underlying cause...
View ArticleFirst-of-Its-Kind Study Uses Smartphone to Track Cystic Fibrosis in Real Life
BETHESDA, Md. -- Today, the Cystic Fibrosis Foundation announced the initiation of the HERO-2: Home Reported Outcomes Study, a first-of-its-kind, at-home observational study that aims to characterize...
View ArticleCF Foundation Launches New Collaboration to Overcome Challenges to Developing...
BETHESDA, Md. -- Today, the CF Foundation announced a new collaboration with venture creator Deep Science Ventures, focused on uncovering and designing new technologies with the potential to overcome...
View ArticleU.S. Supreme Court Rules on the Affordable Care Act
Today, the United States Supreme Court issued a decision in California v. Texas, dismissing the case and ultimately protecting key provisions of the Patient Protection and Affordable Care Act...
View ArticleCystic Fibrosis Foundation Announces Changes on Board of Trustees
Today, the Cystic Fibrosis Foundation announced changes on its Board of Trustees, including the election of Jessica Boyd, MD; Dominic J. Caruso; and Paul Motenko as Trustees. James R. Butler, II; Eric...
View ArticleCF Foundation Announces 2021 Impact Grant Recipients
The Cystic Fibrosis Foundation today announced the recipients of its sixth annual Impact Grants, which provide up to $10,000 of funding per year for up to two years to individuals and nonprofit...
View ArticleCF Foundation Launches Lung Transplant Biorepository and Patient Registry
Today, the Cystic Fibrosis Foundation announced the launch of a first-of-its-kind Cystic Fibrosis Lung Transplant Consortium (CFLTC) Biorepository and Registry. The CFLTC Biorepository and Patient...
View ArticleCF Foundation Commits up to $14 Million in Funding to Expand Research...
BETHESDA, Md. -- Today, the Cystic Fibrosis Foundation announced it is expanding its research collaboration with Synspira Therapeutics Inc., committing up to $14 million in additional funding to...
View ArticleCystic Fibrosis Foundation Strikes First-of-Its-Kind Deal With Pioneering...
BETHESDA, Md. -- Today, the Cystic Fibrosis Foundation announced a first-of-its-kind collaboration with Pioneering Medicines, an initiative of Flagship Pioneering, to spur the development of genetic...
View ArticleCF Foundation Invests $3.5 Million in Pulmocide for Development of Novel...
BETHESDA, Md. -- Today, the Cystic Fibrosis Foundation announced its investment of $3.5 million in Pulmocide Limited, a U.K.-based biotech company, to develop an inhaled drug (opelconazole) to prevent...
View ArticleCF Foundation Awards More Than $1.8M to Three Companies for Genetic Therapies...
The Cystic Fibrosis Foundation announced today that it has awarded more than $1.8 million to three companies for early-stage research into potential genetic therapies for cystic fibrosis as part of its...
View ArticleCF Foundation Awards Up to $4.7M to EnBiotix Inc. to Develop Inhaled...
Although it is approved in Europe, inhaled colistin is not approved for use in the U.S. Currently, the only approved inhaled antibiotics in the U.S. are tobramycin and aztreonam. However, many people...
View ArticleCF Foundation Awards Up to $5 Million to BiomX for Potential Phage Therapy
BETHESDA, Md. -- The Cystic Fibrosis Foundation announced today that it has awarded up to $5 million to BiomX Inc.read more
View ArticleCystic Fibrosis Foundation Announces Investment in SalioGen Therapeutics to...
BETHESDA, Md. -- The Cystic Fibrosis Foundation announced today that it has invested in SalioGen Therapeutics to support the company’s preclinical research into a novel genetic therapy for cystic...
View ArticleCystic Fibrosis Foundation Awards Up to $3.5M to Arrevus Inc. to Develop...
Pulmonary exacerbations are a sudden worsening of respiratory symptoms caused by lung infections that often require IV antibiotic treatment.read more
View ArticleCF Foundation and Bakar Labs Announce Winners of First-Ever Golden Ticket...
The Foundation and Bakar Labs will support AVECRIS Pte Ltd and Nosis Biological Sciences as they pursue genetic therapies for cystic fibrosis with their novel technologies.read more
View ArticleCystic Fibrosis Foundation Announces Irena Barisic as Next Chief Operating...
BETHESDA, MD. - Today, the Cystic Fibrosis Foundation announced that Irena Barisic has been appointed the next Executive Vice President, Chief Operating and Financial Officer. Ms. Barisic will...
View Article
More Pages to Explore .....